Compare Hilton Hotels Corporation Common Stock (HLT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Novavax Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.94 (market cap $73.63B), while Novavax Inc trades at $8.11 (market cap $1.30B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 56.6× Novavax Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| HLT | NVAX | |
|---|---|---|
Market Cap | $73.63B | $1.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $11.19 |
52-Week Low | $256.75 | $6.22 |
Enterprise Value | $86.12B | $800.50M |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.94, up 0.82% with a bearish technical signal despite recent earnings beats. Revenue grew to $12.04B in 2025 with a net income margin of 12.56%, though the P/E ratio of 49.38 suggests premium valuation. The stock faces headwinds from negative equity and rising debt-to-asset ratio, now at 73.88% for 2025. Analyst consensus remains bullish with a $343.40 price target, and recent news highlights earnings optimism ahead of Q2 2026 results.
Outlook: Strong travel demand and consistent earnings beats support growth, but high leverage and valuation pose risks. Opportunities include brand expansion and operational efficiency, while risks involve debt servicing and economic sensitivity. Investors should weigh analyst optimism against fundamental pressures.
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
